SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug Resistance
Viruses · 2025
DOI: 10.3390/v17081055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Carlota Fernandez-Antunez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, 2650 Hvidovre and Department of Immunolog…. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Drug Resistance, Viral, Alanine, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Candys Foundation, The Region H Foundation, The Novo Nordisk Foundation.
Abstract (Originalsprache)
Various SARS-CoV-2 remdesivir resistance-associated substitutions (RAS) have been reported, but a comprehensive comparison of their resistance levels is lacking. We identified novel RAS and performed head-to-head comparisons with known RAS in Vero E6 cells. A remdesivir escape polyclonal virus exhibited a 3.6-fold increase in remdesivir EC50 and mutations throughout the genome, including substitutions in nsp12 (E796D) and nsp14 (A255S). However, in reverse-genetics infectious assays, viruses harboring both these substitutions exhibited only a slight decrease in remdesivir susceptibility (1.3-fold increase in EC50). The nsp12-E796D substitution did not impair viral fitness (Vero E6 cells or Syrian hamsters) and was reported in a remdesivir-treated COVID-19 patient. In replication assays, a subgenomic replicon containing nsp12-E796D+nsp14-A255S led to a 16.1-fold increase in replication under remdesivir treatment. A comparison with known RAS showed that S759A, located in the active site of nsp12, conferred the highest remdesivir resistance (106.1-fold increase in replication). Nsp12-RAS V166A/L, V792I, E796D or C799F, all adjacent to the active site, caused intermediate resistance (2.0- to 11.5-fold), whereas N198S, D484Y, or E802D, located farther from the active site, showed no resistance (≤2.0-fold). In conclusion, our classification system, correlating replication under remdesivir treatment with RAS location in nsp12, shows that most nsp12-RAS cause moderate resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, 2650 Hvidovre and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University…
- Department of Veterinary and Animal Sciences, University of Copenhagen, 1870 Frederiksberg, Denmark.
ORCID-Profile: Carlota Fernandez-Antunez, Jens Bukh, Santseharay Ramirez
Förderung
- Candys Foundation
- The Region H Foundation
- The Novo Nordisk Foundation
- Independent Research Fund Denmark
- Danish Agency for Science and Higher Education
- The Mauritzen La Fontaine Fonden
- Sygeforsikring "danmark"
- Region H Foundation
Zitieren
APA
Fernandez-Antunez, C., Ryberg, L. A., Wang, K., Pham, L. V., Mikkelsen, L. S., Fahnøe, U., Hartmann, K. T., Jensen, H. E., Holmbeck, K., Bukh, J., & Ramirez, S. (2025). SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug Resistance. Viruses. https://doi.org/10.3390/v17081055
Vancouver
Fernandez-Antunez C, Ryberg LA, Wang K, Pham LV, Mikkelsen LS, Fahnøe U, et al. SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug Resistance. Viruses. 2025. doi:10.3390/v17081055
BibTeX
@article{FernandezAntunez2025,
author = {Fernandez-Antunez, Carlota and Ryberg, Line A and Wang, Kuan and Pham, Long V and Mikkelsen, Lotte S and Fahnøe, Ulrik and Hartmann, Katrine T and Jensen, Henrik E and Holmbeck, Kenn and Bukh, Jens and Ramirez, Santseharay},
title = {SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug Resistance},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17081055}
}
EUVIMED